Blog

Last week, the Ministry of Health quietly marked a historic milestone: it granted a license to Christchurch-based psychiatrist Professor Cameron Lacey to prescribe psilocybin for treatment-resistant depression. This is the first time the psychedelic compound will be legally prescribed in New Zealand outside of a clinical trial.

The reemergence of psychedelic therapy presents a rare opportunity to reimagine psychiatry’s epistemic foundations. Rather than simply repackaging these substances within a biomedical framework, this moment should prompt critical interrogation of the assumptions underlying dominant models of mental illness and healing.

Current regulation frameworks for medicines struggle to address the combination of pharmacological and psychotherapeutic elements in psychedelic therapy.

As our societies grapple with environmental and mental health challenges, investigating potential avenues for restoring relations with nature is more important than ever.

The increasing incidence of opioid dependence linked to the consumption of unwashed poppy seeds (UPSs) is an emerging public health concern.

Last week, the Ukrainian Ministry of Health took an important step toward enabling scientific research with psychedelics.

When the email invite came I thought it was a hoax so I contacted Wolf Singer – another neuroscientist. He reassured me it was for real, an

The past 50 years have seen remarkable advances in the science of medicine. The pharmacological treatments of disorders such as hypertension

The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4-methylenedioxymethamphetamine (MDMA)

Authors Ksenia Cassidy, CJ Healy, Eva Henje and Wendy D’Andrea Published March 20, 2024 Abstract Challenging experiences in ayahuasca...

Pioneering research highlights the potential for treating the symptoms of Premenstrual Dysphoric Disorder (PMDD). Written by Eleanor...

Minorities’ diminished psychedelic returns: Cardio-metabolic health. Race differences remain a critically understudied gap in psychedelic li

Terminal patients are calling for compassionate access to be granted for psilocybin — the psychedelic substance found in fungi known as ‘mag

Read our latest report on why patients experiencing 'Existential Distress' ought to be permitted access to psilocybin-assisted psychotherap

On February 3, 2023, the Therapeutic Goods Administration (TGA), Australian Government Department of Health and Aged Care, announced that on

PTSD in adolescence causes much suffering and has substantial health-care costs. The purpose of this study is to investigate the perspective

Psilocybin has shown promise as a treatment for existential distress, a condition marked by feelings of hopelessness, despair, and a lack of

Although there is a growing support for the use of psychedelics to improve the health of marginalized groups, there are some critical gaps.

5-methoxy-N,N-dimethyltryptamine, or ‘toad venom’ as it’s better known, is a tryptamine psychedelic that occurs naturally in multiple specie

Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now

In recent years, the historical record of psychedelic therapy in Europe and the Americas has undergone considerable revision.